Zometa
Zoledronic Acid · Bone-Modifying Agent / Bisphosphonate / RANKL Inhibitor
Indications & Uses
Prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma; hypercalcemia of malignancy.
Contraindications
Hypersensitivity to active ingredient or any formulation excipients.
Side Effects & Warnings
Hypocalcemia, osteonecrosis of the jaw (ONJ), atypical femoral fractures, musculoskeletal pain.
Drug & Dietary Interactions
Caution with strong CYP3A inhibitors or inducers; review concurrent medications.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Patient & Caregiver Support
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.